Heterozygous germline mutations in PTEN are responsible for most cases of Cowden Syndrome, a rare familial trait characterized by hamartomas and by predisposition to cancer of the breast and thyroid. The variable and often subtle clinical ®ndings that characterize Cowden Syndrome are frequently unrecognized, raising the possibility that germline PTEN mutations may confer susceptibility to breast cancer in women who have not been diagnosed with this syndrome. To determine whether such mutations contribute to genetic predisposition to breast cancer within the general population, we analysed a cohort of women with early-onset breast cancer (5age 40), a subset of the population at increased risk for genetic susceptibility. Lymphoblast cell lines were analysed using either direct nucleotide sequencing (28 cases), denaturing gradient gel electrophoresis (DGGE) (34 cases) or a yeast-based truncation assay (110 cases). No de®nitive, truncating mutations were observed in 172 patients. Missense changes were noted in the germline of 2/60 patients analysed by direct nucleotide sequencing or DGGE, including a nonconservative amino acid substitution within the phosphatase domain, but neither showed loss of the wild-type allele in the corresponding breast tumor specimen. We conclude that germline mutations in PTEN are an uncommon cause of genetic predisposition to breast cancer within the general population.
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Keywords: PTEN/MMAC1; Cowden syndrome; breast cancer; genetic predisposition; yeast truncation assay Introduction PTEN (also called MMAC1 and TEP1) is a novel tumor suppressor gene at chromosome 10q23 Steck et al., 1997; Li and Sun, 1997) , that encodes a dual speci®city phosphatase (Myers et al., 1997) and is frequently mutated in glioblastomas, melanoma, and in cancers of the breast, thyroid, prostate, kidney and endometrium Steck et al., 1997; Kong et al., 1997; Rhei et al., 1997; Guldberg et al., 1997; Tashiro et al., 1997; Wang et al., 1997; Rasheed et al., 1997; Dahia et al., 1997; Feilotter et al., 1998a; Durr et al., 1998) . Approximately half of PTEN mutations in these tumors result in a premature stop codon (i.e. truncating mutations), and some missense mutations occur within the conserved phosphatase domain. In addition to somatic mutations, heterozygous germline mutations in PTEN are present in over half of individuals with Cowden Syndrome . This rare familial trait is de®ned by hamartomas, benign tumors that may develop in the skin, thyroid, breast or gastrointestinal tract, together with predisposition to breast and thyroid cancer (Longy and Lacombe, 1996; . Analysis of families with Cowden Syndrome suggests an autosomal dominant cancer predisposition syndrome with high penetrance. PTEN mutations are also present in the germline of individuals with Bannayan ± Zonana Syndrome (BZS), a distinct trait that includes hamartomatous lesions, but which does not demonstrate predisposition to cancer . In the small number of families with either BZS or Cowden Syndrome that have been analysed to date, approximately half of PTEN mutations lead to premature stop codons at comparable positions within the coding region, suggesting that these dierent syndromes may result from the contribution of modifying genes or epigenetic factors. Within families with Cowden Syndrome, the number, location, and size of hamartomas varies considerably, making the clinical diagnosis dicult and suggesting that this genetic trait may often be unrecognized. Together with the presence of PTEN mutations in *15% of sporadic breast cancers, these considerations have raised the possibility that germline mutations in PTEN contribute to predisposition to breast cancer within the general population.
Mutational analysis of cancer predisposition genes using a cohort of breast cancer cases diagnosed at an early age and unselected for a positive family history allows determination of the contribution of these genes to the development of breast cancer within a high risk subset of the general population. Consistent with the Knudson model (Knudson, 1971) , epidemiologic studies have predicted that 36% of women with breast cancer diagnosed under age 40 may harbor a germline mutation in a cancer susceptibility gene, compared with 51% of women diagnosed after age 80 (Claus et al., 1991) . Using a cohort of women with early-onset breast cancer, we have previously detected de®nitive, truncating BRCA1 mutations in 12% of cases and BRCA2 mutations in 2.7% (FitzGerald et al., 1996; Krainer et al., 1997) . To determine the contribution of germline mutations in PTEN to early-onset breast cancer within the general poulation, we used three mutational detection techniques: direct nucleotide sequencing, DGGE, and a yeast-based protein truncation assay .
Results and discussion
We ®rst analysed immortalized lymphoblasts from 28 women with early-onset breast cancer using automated nucleotide sequencing of uncloned PCR products, optimized for detection of heterozygous mutations (see Materials and methods). A cDNA-based strategy was developed, circumventing a processed pseudogene cPTEN on chromosome 9p21 which has 98.5% sequence identity with the PTEN transcript (Dahia et al., 1998) and which has led to confusion in previous mutational analyses (Rhei et al., 1997) . No de®nitive mutations resulting in premature stop codons were detected. In two cases, heterozygous missense changes were identi®ed: C to T at nucleotide 286 (Pro96Ser) and C to T at nucleotide 1202 (Thr401Ile) (see Table  1 ). These mutations have not been previously detected as polymorphisms in the population. The mutation at codon 96 results in a non-conservative amino acid substitution within the phosphatase domain of PTEN. However, analysis of the paran-embedded tumor specimen did not show loss of the wild-type PTEN allele. The mutation at codon 401 arose in a patient with a known truncating mutation in BRCA1, and also did not show loss of heterozygosity in the corresponding breast cancer specimen. In fact, both tumors demonstrated loss of the mutant allele, presumably resulting from loss of heterozygosity driven by a neighboring locus (Feilotter et al., 1998b) . The functional consequences of these missense mutations are therefore unknown. Review of clinical data did not indicate that either of these patients had previously unrecognized features of Cowden Syndrome.
We examined immortalized lymphoblasts from another 34 cases of early-onset breast cancer for heterozygous PTEN mutations by DGGE. Assay conditions were optimized for analysis of individual exons ampli®ed by PCR from genomic DNA, avoiding known polymorphisms within¯anking introns (see Materials and methods) . No cases demonstrated abnormal migration, under conditions that reliably detected sequence variants in patients with Cowden Syndrome.
To extend our analysis using a rapid, high throughput approach speci®cally designed to identify de®nitive, chain-terminating mutations, we adapted a yeast-based protein truncation assay ) (see Figure  1) . One hundred and thirty-eight women with earlyonset breast cancer were screened, including the 28 cases previously analysed by direct nucleotide sequencing and an additional 110 cases with breast cancer diagnosed 5age 40. The entire coding region of PTEN was ampli®ed by RT ± PCR, using tailed oligonucleotide primers that allowed in-frame insertion of the PCR product into the yeast URA3 gene by homologous recombination (see Materials and methods). Yeast transformants were scored for their ability to grow in the absence of uracil, indicating that the inserted PTEN coding region contains an open reading frame, or for failure to grow, resulting from the presence of a stop codon within the PTEN sequence that disrupts translation of the downstream URA3 transcript. In this assay, which has been used to detect truncating mutations in APC and BRCA1 Ishioka et al., 1997) , specimens with homozygous wildtype transcript yield 485% ura+ colonies, while those with a heterozygous truncating mutation yield 40 ± 60% ura+ colonies, and those with a homozygous mutation produce 510% ura+ colonies. The absence of truncating PTEN mutations was con®rmed by yeastassay in the 28 cases that had been analysed by direct nucleotide sequencing. No heterozygous truncating mutations were detected in lymphoblasts from the additional 110 women with early-onset breast cancer.
In summary, we have not detected de®nitive, chainterminating PTEN mutations in the germline of 172 women with early-onset breast cancer. Of 62 of these cases that were analysed using techniques capable of detecting missense mutations, two amino acid substitutions were noted, including one within the phosphatase domain, although neither of these heterozygous germline mutations showed reduction to homozygosity within the corresponding breast tumor specimens. The contribution of constitutional mutations in PTEN toward genetic predisposition to breast cancer within the general population therefore appears to be low. The prevalence of Cowden Syndrome itself within the Lacombe, 1996; . As for other breast cancer predisposition genes, population-based studies will be required to de®ne the clinical spectrum of Cowden Syndrome and the associated risk for breast and thyroid cancer. The rapid screening approaches for PTEN mutations described here should facilitate the molecular characterization of this genetic trait.
Materials and methods

Study population
The cohort of 418 women with early onset of breast cancer identi®ed through Boston area hospitals has been described previously (FitzGerald et al., 1996) . As predicted, these women have clinical characteristics consistent with a high risk for genetic predisposition (19% with an aected ®rst degree relative, 7% with a strong family history of breast cancer, 5% with bilateral breast cancer). Lymphoblast specimens from 28 women diagnosed 5 age 30 were Figure 1 Schematic representation of yeast-based protein truncation assay. The yeast-based stop codon assay , involving construction of a chimeric fusion between the yeast URA3 gene and a PCR-ampli®ed coding sequence, has been used to detect heterozygous germline truncating mutations in the APC and BRCA1 genes Ishioka et al., 1997) . To facilitate analysis of PTEN, and any other gene of interest, we have modi®ed this technique by using a synthetic 45-nucleotide tail at the 5' end of the oligonucleotide primers, which is sucient to allow homologous recombination in yeast. Thus, RT ± PCR ampli®cation of the PTEN transcript from clinical specimens using tailed primers (hatched boxes) produces a single fragment, containing the entire coding region, and¯anked by 45-nucleotide tails that are identical to the sequence¯anking a gap in the yeast pCI-HA(URA3)-2 plasmid . Transformation of yeast with the PCR product together with the linearized vector leads to homologous recombination between the 45-nucleotide sequences, allowing selection for growth in the absence of leucine of transformants expressing the yeast LEU2 gene from the recircularized plasmid. Yeast transformants that have a wild-type PTEN coding region inserted within the URA3 gene also grow in the absence of uracil, while those that have a nonsense or frameshift mutation in the inserted sequence require uracil for growth, allowing for rapid and high throughput screening. Analysis of patients with a germline heterozygous truncating mutation leads to *50% of yeast with the ura+ phenotype analysed by direct nucleotide sequencing of the PTEN coding region and by yeast-based protein truncation assay. An additional 110 women from this cohort, diagnosed 5 age 40, were analysed by yeast protein truncation assay. Thirty four specimens from a similar cohort of women diagnosed with breast cancer 5 age 30 were analysed by DGGE.
Direct nucleotide sequencing
The entire coding region of PTEN was ampli®ed by RT ± PCR from Epstein ± Barr virus-immortalized lymphoblasts.
To prevent coampli®cation of the cPTEN pseudogene (Dahia et al., 1998 ) from contaminating genomic DNA, an initial long RT ± PCR ampli®cation was performed using primers complementary to the extreme 5' and 3' sequences of the PTEN/MMAC1 transcript using primers 8F(ATGCGCTGCGGCAGGATACG) and 3R(TTCCCC-TCCATTGCCCTAACCC). PCR ampli®cation was performed using 35 cycles of 958C610 s, 608C615 s, and 728C63 min. Products of the initial PCR reaction were diluted 1/100 and subjected to nested PCR reactions to generate four overlapping fragments, B, C, D and E for use as sequencing templates (35 cycles of 958C610 s, 538C615 s and 728C62 min). PCR primers were as follows: BF-TTCTGCCATCTCTCTCCTCC, BR-TTGC-TGCAACATGATTGTCA, CF-AACCCACCACAGCTA-GAACTT, CR-TATATCTTCACCTTTAGCTGGC, DF-GATGTTTGAAACTATTCCAATG, DR-CTTTGTCTT-TATTTGCTTTGTC, EF-ATAGAGCGTGCAGATAAT-GACA ER-CATGGTGTTTTATCCCTCTTG. Each forward primer was tailed with the M13-21 primer sequence (TGTAAAACGACGGCCAGT) and each reverse with the M13-28 primer sequence (AGGAAACAGCTATGAC-CAT) for Energy Transfer Dye Primer sequencing (Amersham, Cleveland, OH) according to the manufacturers instructions. Factura and Sequence Navigator (Perkin Elmer) were used to mark potential heterozygous positions and display them for evaluation. Heterozygotes were called at positions where the secondary peak's height is greater than or equal to 30% of the primary peak's height in both sense and antisense sequence reads. To analyse loss of heterozygosity in formalin-®xed, paran-embedded breast tumor specimens, 10 micron slices of tumor were microdissected, treated with xylene, rehydrated, phenolchloroform extracted and ethanol precipitated, followed by PCR-ampli®cation of individual exons and DNA sequencing.
Denaturing gradient gel electrophoresis (DGGE)
DGGE primer design was based on theoretical melting maps generated using an automated version of the original MELT87 software of Lerman and Silverstein (1987) . CG; and [gc13] CGT CCC GC. PCR conditions included à hot start' of 948C for 2 mins, followed by 35 cycles of 948C640 s, annealing at 458C61 min, extension at 728C650 s, and a ®nal 10 mins at 728C. Heteroduplexing of PCR products was allowed to proceed at 988C68 min, 558C630 min and 408C630 min. The ®nal concentrations of PCR reagents were as follows: 16PCR buer (Gibco BRL), 1.5 mM MgCl 2 (except exon 5 which requires 3.0 mM MgCl 2 ), 0.5 mM dNTP, 0.5 mM primer, 5% formamide, and 2.5 units Taq polymerase (Gibco BRL). PCR products were resolved by electrophoresis through 10% polyacrylamide, with a gradient of 20 ± 50% urea/ formamide and 0 ± 10% glycerol, at 100 volts and 608C for 16 h. DGGE fragments were visualised under UV transillumination after staining SYBR green (Molecular Probes, Eugene, OR) for 30 min. DGGE analysis was validated by ready detection of PTEN mutations in the germline of patients with Cowden's syndrome and known mutations.
Yeast-based protein truncation assay
Analysis of the PTEN coding region for truncating mutations was performed by adapting a yeast-based assay . This assay is based on using homologous recombination in yeast to insert a heterologous PCR-generated coding sequence into the yeast URA3 gene. Homologous recombination achieves separation of transcripts derived from wild-type and mutant alleles, and leads to uracil-independent growth in yeast transformants that express a chimeric URA3 gene with an inserted PTEN transcript encoding an open reading frame, but absence of growth in those whose inserted PTEN coding region contains a stop codon. The entire PTEN coding region was ampli®ed from lymphoblast total cellular mRNA by RT ± PCR, using an initial PCR ampli®cation with primers complementary to the extreme 5' and 3' noncoding sequences to exclude ampli®cation of the highly conserved cPTEN pseudogene (Dahia et al., 1998) (see primers and conditions above). This initial PCR product was then diluted 1/100 and subjected to a nested PCR reaction whose primers are complementary to the PTEN coding region and include 5' tails of 45 nucleotides that preserve the open reading frame and are identical to the sequencē anking an engineered BamHI site within the yeast URA3 gene (Primers PTENYHR-F: TTCCTGACTATGCGGGC-TATC C CTATGACGTCCCGGACTATGCAGTGACAG-CCATCATCAAAGAGA; PTENYHRR: GCAGCAACA-G GACTAG GATG AGTAGCAGCACGT TC CT TATAT-GTGCAGACTTTTGTAATTTGTGTATGC. PCR products were transformed into competent yeast (strain YPH499, Stratagene), together with the BamHI-digested yeast expression vector pCI-HA(ura3)-2 . Homologous recombination between the PCR product and the linearized vector leads to insertion of the PTEN coding region within the URA3 gene and to recircularization of the plasmid. Presence of the yeast LEU gene in the plasmid confers upon transformants the ability to grow in the absence of leucine. Transformants that have incorporated into URA3 a PTEN coding region with an open reading frame also demonstrate growth in the absence of uracil, while those that have a stop codon in the PTEN transcript require uracil for growth. Testing of the assay using known wild-type and mutant PTEN PCR products demonstrated 90 ± 100% ura+ colonies following ampli®cation of wild-type alleles, 0 ± 10% ura+ colonies for homozygous mutant alleles.
